Dual-energy X-ray absorptiometry in clinical practice: New guidelines and concerns

Current Opinion in Rheumatology

Volumn 23, Issue 4, 2011, Pages 385-388

  Tanner, Simpson Bobo ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

bone density monitoring; dual energy X ray absorptiometry; guidelines; medicare; osteoporosis; United States Preventive Services Task Force

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

ARTICLE; BODY MASS; BONE DENSITY; CLINICAL PRACTICE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH SERVICE; HIP FRACTURE; HUMAN; MEDICAL DECISION MAKING; MEDICARE; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; SIGNAL NOISE RATIO; UNITED STATES;

ABSORPTIOMETRY, PHOTON; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINES AS TOPIC; REIMBURSEMENT MECHANISMS;

EID: 79958784164     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328347d90c     Document Type: Article

References (26)

1. Clinical indications for bone mass measurements. J Bone Miner Res 1989; 4:1-28.
2. Department of Health and Human Services. Medicare coverage of and payment for bone mass measurements. Washington, District of Columbia: Federal Registry 1998. 34320-34328.
3. Medicare and Medicaid Extenders Act of 2010. Public Law 111-309 In: U.S. Congress, editor. Congressional record. Vol. 156; 2010.
4. Curtis JR, Laster AJ, Becker DJ, et al. Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries. J Clin Densitom 2008; 11:568-574.
5. Oppermann B, Ayoub W, Newman E, et al. Consultative DXA reporting improves guideline-driven quality of care-implications for decreasing DXA reimbursement. J Clin Densitom 2010; 13:315-319.
6. Hayes BL, Curtis JR, Laster A, et al. Osteoporosis care in the United States after declines in reimbursements for DXA. J Clin Densitom 2010; 13:352-360.
7. Curtis JR, Laster A, Becker DJ, et al. The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int 2009; 20:1553-1561.
8. United States Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Rockville, Maryland: United States Preventive Services Task Force; 2002.
9. Screening for osteoporosis: US preventive services task force recommendation statement. Ann Int Med 2011; 154:356-364.
10. Watts NB. Understanding the Bone Mass Measurement Act. J Clin Densitom 1999; 2:211-217.
11. International Society for Clinical Densitometry. International Society for Clinical Densitometry (ISCD) official positions. 2007. www.iscd.org/ Visitors/positions/OfficialPositionsText.cfm. [Accessed 3 April 2011]
12. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, District of Columbia: National Osteoporosis Foundation; 2008.
13. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 2003; 9:544-564.
14. Frost SA, Nguyen ND, Center JR, et al. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res 2009; 24:1800-1807.
15. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008; 19:1362-1368.
16. Bell KJ, Hayen A, Macaskill P, et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009; 338:b2266.
17. Sharma U, Stevermer J. Bisphosphonate therapy: when not to monitor BMD. J Fam Pract 2009; 58:594-596.
18. Compston J. Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ 2009;338:1511-1513.
19. Compston J. Monitoring osteoporosis treatment. Best Pract Res Clin Rheu-matol 2009; 23:781-788.
20. Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009; 24:1643-1646.
21. Lewiecki EM. Bone density testing to monitor osteoporosis therapy in clinical practice. Am Fam Physician 2010; 82:749-750.
22. Adler RA, Favus MJ. Following BMD in patients on bisphosphonates: another perspective. J Bone Miner Res 2009; 24:1647-1648.
23. Bell KJL, Hayen A, Irwig L, et al. The value of routine BMD monitoring after starting bisphosphonate treatment. J Bone Miner Res 2010; 25:173-174.
24. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of post menopausal osteoporosis. Endocr Pract 2010; 16 (Suppl 3):1-37.
25. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-1526.
26. Bonnick SL. Bone densitometry in clinical practice: application and interpretation (current clinical practice series). 3rd ed. Totowa, New Jersey: Humana Press; 2010